Jianjun Zhang
M.D. Anderson Cancer Center · RenJi Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jianjun Zhang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07038915 · STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1M.D. Anderson Cancer Center · withdrawn · Lung Squamous Cell Carcinoma, Anti-PD1/PDL1 Antibody · principal investigator
- Ph4NCT06353126 · DEB-TACE Prior to Liver Transplantation in the Treatment of HCCRenJi Hospital · recruiting · Liver Cancer · principal investigator
- N/ANCT06069037 · SALT for Treatment of Patients With Early ACLFRenJi Hospital · unknown · Acute-On-Chronic Liver Failure · principal investigator
- Ph2NCT04789681 · Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung TrialM.D. Anderson Cancer Center · recruiting · Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8 · principal investigator
- Ph2NCT03634241 · Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung StudyM.D. Anderson Cancer Center · completed · Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic responseU01CA256780 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2025 · $605,520 awarded in 2025Same name and institution; not confirmed by an ID
- The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinomaR01CA234629 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2023 · $358,680 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:02 UTC. The ranking covers the 200 most relevant of 4271 PubMed records, and a shared surname and initials can bring in a namesake. All 4271 on PubMed
- 163 citationsRCR 33.1
- 47 citationsRCR 7.3
- Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.Ann Oncol · 202645 citationsRCR 22.5
- Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Ann Oncol · 202637 citationsRCR 18.5
- 31 citationsRCR 8.0
- Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery: The BP-CARES Randomized Trial.J Am Coll Cardiol · 202530 citationsRCR 13.9
- Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial.JAMA Dermatol · 202524 citationsRCR 7.3
- Probiotic-induced enrichment of Adlercreutzia equolifaciens increases gut microbiome wellness index and maps to lower host blood glucose levels.Gut Microbes · 202524 citationsRCR 7.4
- Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.J Thorac Oncol · 202522 citationsRCR 4.3
- 22 citationsRCR 11.0